Proper classification of the p53 T253I mutation as an LFS-associated pathogenic variant is important to develop a rational cancer-preventive and early surveillance plan to improve clinical outcomes for our patient, their family and for other patients with germline p53 T253I mutations. The gene discussed is TP53; the disease is cancer.